



**Amarantus**  
BioSciences

**MEDIA CONTACTS:**

Amarantus BioSciences, Inc.

Gerald E. Commissiong

408.737.2734 x 102

pr@amarantus.com

**Amarantus BioSciences' Gerald and Dr. John Commissiong Selected as Black Money's "50 Most Important African-Americans in Technology"**

**SUNNYVALE, CA – November 15, 2011** – Amaranthus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced that both Gerald and Dr. John Commissiong are among the Bay Area selectees for the 12<sup>th</sup> Annual 50 Most Important African-Americans in Technology. The selectees will gather in Washington, D.C. January 14-15, 2012 for the 12<sup>th</sup> Annual Innovation and Equity Symposium themed: "Capitalizing Creativity: Innovation and Job Creation." At the Innovation and Equity Symposium, participants will discuss a variety of relevant topics relating to African-Americans including the new America Invents Act and the low participation of African-American students in math and science courses.

"We have worked tremendously hard over the past several years to discover, patent and develop molecules to treat patients suffering from Parkinson's and other CNS diseases," said John Commissiong, Chief Scientific Officer of Amaranthus. "We are honored to be recognized for our efforts as part of this prestigious group."

Amarantus was also among the companies participating in the Catapult Innovation Showcase, an effort to identify the most promising high growth, job creating companies among the 1,000 patents gained each year by African-Americans. Amaranthus recently received a Notice of Allowance from the U.S. Patent & Trademark Office covering MANF's discovery and therapeutic applications, which complements the Company's existing patent portfolio in Europe and global patent-pending portfolio. Amaranthus' most advanced program is focused on developing MANF as a disease-modifying therapy for Parkinson's disease.



**Amarantus**  
BioSciences

### **About Black Money's 50 Most Important African-Americans in Technology**

The listing of the 50 Most Important African-Americans in Technology began with an exhibition at The Tech Museum of Innovation in San Jose, California in 1998 to share the long-overlooked role of African-Americans in industrial innovation since the 19th century through the high-tech age. The 2011 selectees represent a fourth wave of innovation which has shaped the development of the U.S. economy. The 9<sup>th</sup> Annual Innovation and Equity Symposium featured the technical legacy of the Freedom Riders of the Cutting Edge -- Roy Clay Sr., a Silicon Valley Engineering Hall of Fame member; and the late Dr. Frank Greene Sr., Gerald A. Lawson and Ron Jones. Far too often overlooked, they are a key motivational force for increasing the participation of African-American students in mathematics and science courses. The 10<sup>th</sup> Annual Innovation & Equity Symposium led to the development of a biotechnology pilot high school in San Francisco. The 11<sup>th</sup> Annual Symposium was followed by testimony on Capitol Hill regarding African-American innovation, and the Catapult Innovation Showcase across the nation spurred manufacturing through innovation in black communities. Additionally, 'A Great Day in Gaming: From Queens to Silicon Valley: The Gerald A. Lawson Story' debuted in June at The Tech Museum of Innovation, just three months after his visit to the Game Developers Conference in March. More details on the 50 Most can be found at <http://www.souloftechnology.com> or <http://www.blackmoney.com>

### **About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)**

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.

### **About Amarantus BioSciences, Inc.**

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and



**Amarantus**  
BioSciences

other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit [www.amarantus.com](http://www.amarantus.com).

### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.